UY30838A1 - Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide - Google Patents
Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoideInfo
- Publication number
- UY30838A1 UY30838A1 UY30838A UY30838A UY30838A1 UY 30838 A1 UY30838 A1 UY 30838A1 UY 30838 A UY30838 A UY 30838A UY 30838 A UY30838 A UY 30838A UY 30838 A1 UY30838 A1 UY 30838A1
- Authority
- UY
- Uruguay
- Prior art keywords
- monoclonal antibody
- diagnosis
- treatment
- rheumatoid arthritis
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
La presente invencion se relaciona con la rama de la Inmunología y en particular con la obtancion de composiciones farmacéuticas que contienen un Anticuerpo Monoclonal humanizado que reconoce el antígeno de diferenciacion leucocitario CD6. De acuerdo con lo expuesto, el objeto de eta invencion es proporcionar composiciones farmacéuticas que contengan un Anticuerpo Monoclonal humanizado anti-CD6 para el diagnostico y tratamiento de enfermedades autoinmunes en particular la Artritis Reumatoide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20060250 | 2006-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30838A1 true UY30838A1 (es) | 2008-07-31 |
Family
ID=39562112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30838A UY30838A1 (es) | 2006-12-26 | 2007-12-24 | Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide |
Country Status (19)
Country | Link |
---|---|
US (3) | US20100092423A1 (es) |
EP (1) | EP2119452B1 (es) |
KR (1) | KR101482956B1 (es) |
CN (2) | CN105251004A (es) |
AR (1) | AR064527A1 (es) |
AU (1) | AU2007336563B2 (es) |
CA (1) | CA2676185C (es) |
DK (1) | DK2119452T3 (es) |
ES (1) | ES2785043T3 (es) |
HK (1) | HK1213782A1 (es) |
IT (1) | ITTO20070942A1 (es) |
MY (1) | MY165625A (es) |
NZ (1) | NZ578635A (es) |
PE (1) | PE20081553A1 (es) |
PL (1) | PL2119452T3 (es) |
PT (1) | PT2119452T (es) |
RU (1) | RU2472526C2 (es) |
UY (1) | UY30838A1 (es) |
WO (1) | WO2008077355A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2993186B1 (en) | 2008-03-14 | 2019-09-04 | Biocon Limited | A monoclonal antibody and a method thereof |
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
US11037196B2 (en) | 2012-02-24 | 2021-06-15 | Netclearance Systems, Inc. | Interactive advertising using proximity events |
US11062258B2 (en) | 2012-02-24 | 2021-07-13 | Netclearance Systems, Inc. | Automated logistics management using proximity events |
NZ746944A (en) | 2013-07-23 | 2021-07-30 | Biocon Ltd | Use of a cd6 binding partner and method based thereon |
PT3269735T (pt) * | 2015-03-13 | 2020-12-04 | Shanghai hengrui pharmaceutical co ltd | Anticorpo antiesclerotina, fragmanto de ligação a antigénio e seus usos médicos |
KR20180105710A (ko) * | 2016-02-10 | 2018-09-28 | 카이맨 케미칼 컴파니 인코포레이티드 | 항-시트룰린화 hla 폴리펩티드 항체 및 이들의 용도 |
CA3039855A1 (en) | 2016-10-21 | 2018-04-26 | Biocon Limited | A monoclonal antibody and a method of use for the treatment of lupus |
US11151534B2 (en) * | 2016-11-29 | 2021-10-19 | Netclearance Systems, Inc. | Consumer interaction module for point-of-sale (POS) systems |
US11334889B2 (en) | 2016-11-29 | 2022-05-17 | Netclearance Systems, Inc. | Mobile ticketing based on proximity |
CN109903854B (zh) * | 2019-01-25 | 2023-04-07 | 电子科技大学 | 一种基于中医药文献的核心药物识别方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US699755A (en) | 1902-03-06 | 1902-05-13 | Ira G Hoag | Train-order box in connection with semaphores. |
US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
EP0631783A1 (en) * | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
AU703694B2 (en) * | 1993-11-02 | 1999-04-01 | Bristol-Myers Squibb Company | CD6 ligand |
US5423562A (en) * | 1993-11-05 | 1995-06-13 | Pearce, Jr.; Fredric C. | Chair lift |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
US6221907B1 (en) * | 1996-03-20 | 2001-04-24 | Hoechst Marion Roussel | Tricyclic compounds having activity specific for integrins, particularly alphanubeta3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same |
AU747898B2 (en) * | 1997-03-03 | 2002-05-30 | Bristol-Myers Squibb Company | Monoclonal antibodies to human CD6 |
PL200134B1 (pl) * | 1999-05-07 | 2008-12-31 | Genentech Inc | Zastosowanie przeciwciała anty-CD20 |
FI110553B (fi) * | 2001-02-12 | 2003-02-14 | Perlos Oyj | Liitin ja liittimen irtopala |
ES2192128B1 (es) * | 2001-04-27 | 2005-01-01 | Universidad De Vigo | Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia. |
WO2006035876A1 (ja) * | 2004-09-29 | 2006-04-06 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
DK1817340T3 (da) * | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
WO2006071091A1 (en) * | 2004-12-29 | 2006-07-06 | Yuhan Corporation | Humanized antibody specific for tumor necrosis factor-alpha |
-
2007
- 2007-12-24 EP EP07855983.8A patent/EP2119452B1/en active Active
- 2007-12-24 AU AU2007336563A patent/AU2007336563B2/en active Active
- 2007-12-24 WO PCT/CU2007/000021 patent/WO2008077355A1/es active Application Filing
- 2007-12-24 KR KR1020097015726A patent/KR101482956B1/ko active IP Right Grant
- 2007-12-24 RU RU2009128659/15A patent/RU2472526C2/ru active
- 2007-12-24 DK DK07855983.8T patent/DK2119452T3/da active
- 2007-12-24 MY MYPI20092717A patent/MY165625A/en unknown
- 2007-12-24 PT PT78559838T patent/PT2119452T/pt unknown
- 2007-12-24 CN CN201510700301.XA patent/CN105251004A/zh active Pending
- 2007-12-24 NZ NZ578635A patent/NZ578635A/en unknown
- 2007-12-24 CN CN200780050236A patent/CN101657215A/zh active Pending
- 2007-12-24 UY UY30838A patent/UY30838A1/es unknown
- 2007-12-24 PL PL07855983T patent/PL2119452T3/pl unknown
- 2007-12-24 US US12/525,442 patent/US20100092423A1/en not_active Abandoned
- 2007-12-24 ES ES07855983T patent/ES2785043T3/es active Active
- 2007-12-24 CA CA2676185A patent/CA2676185C/en active Active
- 2007-12-26 AR ARP070105894A patent/AR064527A1/es unknown
- 2007-12-27 IT IT000942A patent/ITTO20070942A1/it unknown
-
2008
- 2008-01-02 PE PE2008000036A patent/PE20081553A1/es not_active Application Discontinuation
-
2014
- 2014-04-14 US US14/252,002 patent/US20160024220A1/en not_active Abandoned
-
2016
- 2016-02-18 HK HK16101786.8A patent/HK1213782A1/zh unknown
- 2016-11-16 US US15/352,982 patent/US20170066835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR064527A1 (es) | 2009-04-08 |
KR101482956B1 (ko) | 2015-01-15 |
ES2785043T3 (es) | 2020-10-05 |
US20170066835A1 (en) | 2017-03-09 |
CA2676185A1 (en) | 2008-07-03 |
PT2119452T (pt) | 2020-05-08 |
NZ578635A (en) | 2012-03-30 |
HK1213782A1 (zh) | 2016-07-15 |
RU2472526C2 (ru) | 2013-01-20 |
EP2119452B1 (en) | 2020-03-04 |
US20160024220A1 (en) | 2016-01-28 |
PE20081553A1 (es) | 2008-12-10 |
CA2676185C (en) | 2013-03-12 |
WO2008077355A1 (es) | 2008-07-03 |
ITTO20070942A1 (it) | 2008-06-27 |
CN105251004A (zh) | 2016-01-20 |
RU2009128659A (ru) | 2011-02-10 |
AU2007336563A1 (en) | 2008-07-03 |
EP2119452A1 (en) | 2009-11-18 |
AU2007336563B2 (en) | 2012-11-01 |
DK2119452T3 (da) | 2020-04-20 |
CN101657215A (zh) | 2010-02-24 |
KR20090122910A (ko) | 2009-12-01 |
EP2119452A4 (en) | 2012-06-06 |
MY165625A (en) | 2018-04-18 |
PL2119452T3 (pl) | 2021-03-08 |
US20100092423A1 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30838A1 (es) | Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide | |
PE20161327A1 (es) | Proteinas de enlace al antigeno il-23 humana | |
AR053514A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
PE20081478A1 (es) | Anticuerpos cd44 | |
PE20130159A1 (es) | Anticuerpos anti-cd40 | |
PE20160553A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
CR11116A (es) | Nuevos compuestos | |
CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
PE20140247A1 (es) | Anticuerpos anti-cd38 | |
EA201791127A1 (ru) | Антитела, содержащие модифицированные константные участки тяжелой цепи | |
GT200600043A (es) | Variantes de un anticuerpo y usos de las mismas | |
BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
AR079458A2 (es) | Anticuerpo monoclonal quimerico que se une a cd45 | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
PE20060418A1 (es) | Anticuerpos antagonistas de il-17 | |
RS53263B (en) | CD19 OPTIMIZED ANTIBODY | |
PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
CR11004A (es) | Anticuerpos anti-esclerotina | |
PE20140633A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
PE20160652A1 (es) | Anticuerpos que se unen a il-17f | |
NI201400019A (es) | Anticuerpo anti-alfabetatcr | |
PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
PE20091342A1 (es) | Inmunoglobulinas | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos |